This company has been marked as potentially delisted and may not be actively trading. IMARA (IMRA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock IMRA vs. MOR, GMTX, CALT, ZYME, MBX, SBTX, AVTE, BIOA, NLTX, and CYBNShould you be buying IMARA stock or one of its competitors? The main competitors of IMARA include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), MBX Biosciences (MBX), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). IMARA vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks MBX Biosciences Silverback Therapeutics Aerovate Therapeutics BioAge Labs Neoleukin Therapeutics Cybin MorphoSys (NASDAQ:MOR) and IMARA (NASDAQ:IMRA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings. Which has more risk & volatility, MOR or IMRA? MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, IMARA has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Do institutionals and insiders have more ownership in MOR or IMRA? 18.4% of MorphoSys shares are held by institutional investors. Comparatively, 49.3% of IMARA shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 37.3% of IMARA shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to MOR or IMRA? In the previous week, MorphoSys' average media sentiment score of 0.00 beat IMARA's score of 0.00 indicating that MorphoSys is being referred to more favorably in the media. Company Overall Sentiment MorphoSys Neutral IMARA Neutral Which has stronger earnings & valuation, MOR or IMRA? IMARA has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than IMARA, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45IMARAN/AN/A$1.49M$0.05738.40 Is MOR or IMRA more profitable? IMARA has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. IMARA's return on equity of 2.12% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% IMARA N/A 2.12%2.00% SummaryIMARA beats MorphoSys on 8 of the 11 factors compared between the two stocks. Get IMARA News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRA vs. The Competition Export to ExcelMetricIMARAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$968.56M$941.20M$5.83B$10.00BDividend YieldN/A4.84%5.28%4.53%P/E Ratio738.551.1275.6926.28Price / SalesN/A26.60544.78188.18Price / Cash75.2419.5637.2059.76Price / Book10.736.7511.506.41Net Income$1.49M-$4.20M$3.28B$270.56M IMARA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRAIMARAN/A$36.92+4.1%N/AN/A$968.56MN/A738.5541MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$59.650.0%N/A+23.0%$2.58BN/A-59.6530CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.3962 of 5 stars$14.01-5.4%$21.43+53.0%+30.2%$1.05B$122.87M-9.34460Positive NewsMBXMBX Biosciences2.8237 of 5 stars$14.57-3.4%$37.63+158.2%N/A$489.47MN/A-3.2136Positive NewsSBTXSilverback TherapeuticsN/A$11.62-9.6%N/A-8.6%$418.99MN/A-4.8083High Trading VolumeAVTEAerovate TherapeuticsN/A$7.90-2.2%N/A-88.9%$228.98MN/A-2.6420News CoveragePositive NewsHigh Trading VolumeBIOABioAge LabsN/A$4.65-5.7%N/AN/A$176.74MN/A0.00N/APositive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$18.48-1.9%N/A-44.4%$173.68MN/A-5.9490CYBNCybin2.5738 of 5 stars$6.24-16.6%$85.00+1,262.2%N/A$147.20MN/A-1.4250Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives MBX Biosciences Alternatives Silverback Therapeutics Alternatives Aerovate Therapeutics Alternatives BioAge Labs Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRA) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWall Street Legend Issues Urgent AI Stock WarningChaikin's stepping forward with a new warning – focused on the red-hot A.I. frenzy taking the U.S. stock marke...Chaikin Analytics | SponsoredUnlock Friday's Full Potential: Two Simple Sentences that put profits in investors’ pocketsMost traders stick to the same routine each week. But a little-known market strategy has quietly delivered a 9...Eagle Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMARA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMARA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMRA Stock Alerts